Market access pathways by country

Explore how an innovative medicine moves from approval to patient access.

Selected market

Colombia

INVIMA registration and price regulation are followed by either UPC-financed benefits or non-UPC prescription through MIPRES and maximum-budget resources. EPS direction, provider network, dispense and payment close the pathway.

INVIMA / registration holder

IETS / CNPMDM / MinSalud

MinSalud / EPS / prescriber

EPS / member / IPS/pharmaceutical manager

treating professional / EPS

8 decision nodes16 cited sources

For education only — not regulatory, pricing or legal advice.

About the content and how to use it